Recent developments in C3-targeted complement therapeutics

Semin Immunol. 2022 Mar:60:101645. doi: 10.1016/j.smim.2022.101645. Epub 2022 Jul 29.

Authors

Dimitrios C Mastellos¹, John D Lambris²

Affiliations

¹ National Center for Scientific Research "Demokritos", Aghia Paraskevi, Athens, Greece. Electronic address: mastellos@rrp.demokritos.gr.
² Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: lambris@pennmedicine.upenn.edu.

PMID: 35915008
DOI: 10.1016/j.smim.2022.101645

No abstract available

Publication types

Editorial

MeSH terms

Complement Activation
Complement C3*
Complement Inactivating Agents* / pharmacology
Complement Inactivating Agents* / therapeutic use
Humans

Substances

Complement C3
Complement Inactivating Agents